Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1CNS 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Neurofibromatosis 2 1Hemangiosarcoma 1Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has results × Vascular Endothelial Growth Factor A × Clear all
NCT01551745 2021-10-19

Salvage Ovarian FANGâ„¢ Vaccine + Bevacizumab

Gradalis, Inc.

Phase 2 Completed
5 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT01767792 2021-02-12

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

University of Alabama at Birmingham

Phase 2 Completed
22 enrolled 14 charts
CNS

Neurofibromatosis 2

NCT00288015 2018-06-25

Bevacizumab in Treating Patients With Angiosarcoma

Northwestern University

Phase 2 Completed
32 enrolled 12 charts
Sarcoma

Hemangiosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡